Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro
Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro
复制标题
DOI:
10.1016/j.jcrs.2014.08.027
复制
发表时间:
2014-11-01
影响因子:
2.8
通讯作者:
Yamagami, Satoru
中科院分区:
文献类型:
--
作者:
Haruki, Tomoko;Miyazaki, Dai;Yamagami, Satoru
PURPOSE: To evaluate and compare the toxic effects of moxifloxacin, cefuroxime, and levofloxacin on human corneal endothelial cells in vitro and determine the safe intracameral concentrations for them.SETTING: Tottori University, Tottori, Japan.DESIGN: Experimental study.METHODS: Human corneal endothelial cells in culture were exposed to moxifloxacin, cefuroxime, and levofloxacin at concentrations up to 2000 mu g/mL. Evaluation of membrane damage was determined by ethidium homodimer-1 uptake and cell viability, by intrinsic esterase activity. The inhibitory effects of the 3 antibiotics on the constitutive secretion of interleukin-6 (IL-6) by human corneal endothelial cells were determined by enzyme-linked immunosorbent assay.RESULTS: The acute effects (6 hour) of the 3 antibiotics on membrane damage and cell death were dose-dependent for moxifloxacin and levofloxacin (>= 500 mu g/mL). For cefuroxime, membrane damage was not observed at 6 hours and only slight damage was detected at 24 hours at concentrations higher than 500 mu g/mL. The half maximum inhibitory concentrations on cell viability of moxifloxacin, levofloxacin, and cefuroxime were 487 mu g/mL, 578 mu g/mL, and 1600 mu g/mL, respectively. The inhibitory effects of the 3 antibiotics on the constitutive secretion of IL-6 were observed at 15.6 mu g/mL or higher, indicating the antibiotics can impair the secretion of the protective cytokine even at low concentrations.CONCLUSIONS: Moxifloxacin at more than 500 mu g/mL caused damage to the cell membranes of corneal endothelial cells; even higher concentrations decreased cell viability. Considering the lower minimum inhibitory concentration for inhibiting 90% growth by moxifloxacin, intracameral moxifloxacin at 500 mu g/mL or less is recommended for prophylactic use.